Cain J M, Saigo P E, Pierce V K, Clark D G, Jones W B, Smith D H, Hakes T B, Ochoa M, Lewis J L
Gynecol Oncol. 1986 Jan;23(1):14-25. doi: 10.1016/0090-8258(86)90110-1.
One hundred twenty-seven patients underwent second-look laparotomies from July 1969 to June 1982. To be included in this report they must have met the following criteria: a documented ovarian neoplasm; previous surgery; adequate chemotherapy for cessation if no disease was found; and no X-ray, chemical, or clinical evidence of disease including an exam under anesthesia. Forty-one percent had residual disease at second-look laparotomy. The original stage and the percentage of tumor debulked at initial surgery were inversely related to the likelihood of finding residual disease. Age, histologic type and grade, and type of chemotherapy did not show a significant relationship with the likelihood of disease persisting. Recurrent tumor was subsequently detected in 16% of patients who had been found to be free of disease at second-look laparotomy. Of thirty stage III and IV patients treated with combinations containing cis-platinum, 10 (33%) had recurrences. This rate of recurrence was significantly greater than the 17.6% recurrence rate in 17 patients with Stage III and IV disease whose chemotherapy consisted of single alkylating agents or with combinations without cis-platinum. Twenty patients underwent a third-look laparotomy after completion of additional chemotherapy. Nine were found to have no residual disease. Two of the nine (22%) subsequently had recurrence of disease. Three of the eleven patients with persistent disease at the time of a third-look laparotomy underwent a fourth-look laparotomy. All were found free of disease and none have recurred. Six (55%) of those with persistent disease at the third-look laparotomy have died despite continued therapy. The ability to successfully treat some patients with persistent disease continues to be a justification for the use of a second-look laparotomy. However, the high rate of recurrence after cessation of treatment following the finding of no residual disease raises the question of whether it is appropriate to discontinue all therapy at this time.
1969年7月至1982年6月期间,127例患者接受了二次剖腹探查术。纳入本报告的患者必须符合以下标准:有记录的卵巢肿瘤;先前接受过手术;若未发现疾病,则有足够的化疗以实现病情缓解;且无疾病的X线、化学或临床证据,包括麻醉下检查。41%的患者在二次剖腹探查时存在残留疾病。初始手术时的原发病期和肿瘤减灭百分比与发现残留疾病的可能性呈负相关。年龄、组织学类型和分级以及化疗类型与疾病持续存在的可能性无显著关系。在二次剖腹探查时被发现无疾病的患者中,随后有16%检测到复发性肿瘤。在接受含顺铂联合治疗的30例III期和IV期患者中,有10例(33%)复发。这一复发率显著高于17例接受单一烷化剂化疗或不含顺铂联合化疗的III期和IV期疾病患者的17.6%复发率。20例患者在完成额外化疗后接受了三次剖腹探查术。9例被发现无残留疾病。这9例中的2例(22%)随后疾病复发。在三次剖腹探查时仍有持续性疾病的11例患者中有3例接受了四次剖腹探查术。所有患者均被发现无疾病,且均未复发。在三次剖腹探查时仍有持续性疾病的患者中有6例(55%)尽管继续治疗仍死亡。成功治疗一些持续性疾病患者的能力仍然是进行二次剖腹探查术的一个理由。然而,在发现无残留疾病后停止治疗后的高复发率提出了此时是否适合停止所有治疗的问题。